genetic testing and motivational counseling for fh

Conditions: Hypercholesterolemia, Familial; Hypercholesterolemia, Familial, 1; Hypercholesterolemia, Familial, 2; Hypercholesterolemia, Familial, 3; Hypercholesterolemia, Familial, 4; Hypercholesterolemia, Familial, 4, Autosomal Recessive; Familial Hypercholesterolemia With Hyperlipemia; Hypercholesterolemia, Autosomal Dominant, Type B; Hypercholesterolemia, Autosomal Dominant; Hypercholesterolemia, Autosomal Dominant, 3; Apolipoprotein B-100, Familial Defective; Genetic Testing; Motivational Interviewing; Therapeutic Adherence; Therapeutic Adherence and Compliance; Treatment Adherence; Medication Adherence; Treatment Adherence and Compliance; Patient Adherence; Compliance; Patient Compliance; Familial Hypercholesterolemia; Familial Hypercholesterolemia - Heterozygous; Adherence, Patient; Adherence, Medication; Adherence

Summary: to date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of ldl-c in most patients with familial hypercholesterolemia (fh). however, the effectiveness of treatment of fh patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. the aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with fh.

there are several tasks of the study: 1. to assess the effect of knowledge of patients with fh about the result of their fh genetic testing on the adherence to a healthy lifestyle and hypolipidemic therapy. 2. to assess the impact of knowledge of patients with fh about the result of their fh genetic testing on the effectiveness of cascade screening. 3. to assess the influence of motivational counseling of patients with fh on the adherence to a healthy lifestyle and hypolipidemic therapy. 4. to assess the impact of motivational counseling of patients with fh on the effectiveness of cascade screening.

Eligibility criteria:
inclusion criteria: * probable or definite diagnosis of fh according to the dutch criteria (6 points or more); * signed informed consent; exclusion criteria: * pregnancy or lactation at the time of enrollment * established active severe infectious disease or severe hematologic, metabolic, gastrointestinal or endocrine dysfunctions (for example, uncontrolled thyroid dysfunction or uncontrolled diabetes mellitus) in the opinion of the investigator * active liver disease * estimated gfr≤ 30 ml / min / 1.73m2 * any other conditions at visit 1 that, according to the investigator's opinion, render the patient ineligible for inclusion in the study, may interfere with the patient's participation in the study or patient's completion of the study.

Keywords: familial hypercholesterolemia fh genetic testing motivational counseling motivational interviewing cascade screening adherence compliance hypercholesterolemia, familial hypercholesterolemia, familial, 1 hypercholesterolemia, familial, 2 hypercholesterolemia, familial, 3 hypercholesterolemia, familial, 4 hypercholesterolemia, familial, 4, autosomal recessive familial hypercholesterolemia with hyperlipemia hypercholesterolemia, autosomal dominant, type b hypercholesterolemia, autosomal dominant hypercholesterolemia, autosomal dominant, 3 apolipoprotein b-100, familial defective therapeutic adherence therapeutic adherence and compliance patient adherence familial hypercholesterolemia - heterozygous psychological counseling adherence, patient adherence, medication treatment adherence medication adherence treatment adherence and compliance patient compliance